The OSU Comprehensive James Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute will pilot the device for a study on ultra-high dose rate (FLASH) radiotherapy.
The device, developed by IntraOp Medical Corp., delivers high-energy electrons to the region of the patient’s tumor. Pre-clinical testing has shown that FLASH radiotherapy offers various biological benefits and improves therapeutic index by creating a protective effect on normal tissue, according to the July 14 news release.
“Ohio State is extremely well-poised to become the global leader in the development of pan-FLASH clinical capabilities ranging from electrons to protons,” said Arnab Chakravarti, MD, professor and chair of radiation oncology at OSUCCC-James. “We are extremely excited to partner with IntraOp to launch key investigations paving the way for future clinical implementation of FLASH-electrons in this setting.”
More articles on oncology:
Cancer patient deaths lower at higher CMS-rated hospitals, study finds
Georgia hospital to build $7.7M radiation oncology center
Ohio health system, Indiana hospital partner on cancer care
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
